## ISMP Medication Safety Alert Acute Care

> *Best Practices* — continued from page 3

Table 1. Compliance with three new 2022-2023 ISMP Targeted Medication Safety Best Practices for Hospitals (N = 188)

Best Practice*	Percent Compliance		iance	Commonly Reported Barriers (B) and
	None	Partial	Full	Enablers (E) to Implementation
#17. Safeguard against errors with oxytocin use				
Require the use of standard order sets when prescribing	5	12	83	<b>B:</b> Anesthesia staff resistance; allowing prescribers to bypass the order set <b>E:</b> Implement systemwide standard order sets; leadership requiring its use
Standardize to a single concentration for both antepartum and postpartum infusions	7	9	84	<ul> <li>B: Anesthesia staff resistance; supply issues</li> <li>E: Provide a single concentration in the electronic prescribing system and infusion pump drug library</li> </ul>
Standardize how oxytocin doses, concentration, and rates are expressed	4	16	80	<ul> <li>B: Different dose expressions based on the indication</li> <li>E: Standardize dose expressions in order sets and infusion pump drug library</li> </ul>
Communicate infusion orders in terms of the dose rate and align with the smart infusion $pump$ dose error-reduction system (DERS)	5	13	82	<b>B</b> : Workflow challenges; oxytocin excluded from infusion pump interoperability <b>E</b> : Review oxytocin dose rates monthly at medication safety meetings
Provide oxytocin in a ready-to-use form	5	9	86	<ul><li>B: May not be available commercially; supply issues</li><li>E: Pharmacy prepares infusions; purchases infusions from a compounder</li></ul>
Boldly label both sides of the infusion bag to differentiate oxytocin bags from plain hydration and magnesium infusions	49	15	36	B: Infusions purchased from a compounder are only labeled on one side E: None reported
Avoid bringing oxytocin to the bedside until it is prescribed and needed	7	36	57	<ul> <li>B: Staffing shortages; nurse preference to have all emergency supplies in room; nurse unable to leave patient alone to get supplies</li> <li>E: None reported</li> </ul>
#18. Expand the use of barcode verification prior to medi	cation a	nd vaccine	e admini	stration beyond inpatient care areas
Target areas with a short or limited patient stay, such as:				
a. Emergency department	7	28	65	B: Equipment related - Not enough scanning equipment; lack of space
b. Operating rooms (ORs)	38	55	7	for equipment; concerns about sterility or metal objects <b>B: Information technology related</b> - Requires complex rebuilding of the
c. Procedure rooms	24	60	16	<ul> <li>B: Mormation technology related - Negatives complex redulting of the electronic health record; problems with electronic prescribing templates:</li> <li>B: Staffing related - Not enough pharmacists to verify orders; training needs especially with contracted per diem nurses; misperception that scanning is only needed for documentation; perceived increase in time; low compliance</li> <li>B: Workflow related - One-step medication prescribing, administration documentation (no order entry); verbal orders; medications not prepared and barcoded in the pharmacy; patient's identification band under a sterile drape; lack of barcodes on some drugs such as radio pharmaceuticals; medication/solution (e.g., dialysate) not documented on the medication administration record</li> <li>E: None reported</li> </ul>
d. Perioperative holding areas	13	24	63	
e. Post-anesthesia care units (PACU)	9	18	73	
f. Radiology	28	41	31	
g. Labor and delivery	5	23	72	
h. Infusion clinics	16	8	76	
i. Dialysis centers	11	22	67	
j. Cardiac catheterization labs	31	46	23	
Regularly review compliance data and other metrics to assess utilization and effectiveness	0	31	69	<ul> <li>B: Unable to tell if compliance statistics reflect scanning <i>before</i> (appropriate) or <i>after</i> (inappropriate) drug administration</li> <li>E: None reported</li> </ul>
#19. Layer numerous strategies throughout the medication	on-use pi	rocess to i	mprove	the safety with high-alert medications
For each high-alert drug on the facility's list, outline a robust set of processes for managing risk, impacting as many steps of the medication-use process as possible	1	35	64	<ul> <li>B: Difficult to assess all aspects for each drug; lack of time</li> <li>E: Put guidance in an electronic format; address certain medications that have the highest risks to patients first</li> </ul>
Ensure that the strategies address vulnerabilities in each stage of the medication-use process and apply to all involved disciplines	1	36	63	<ul> <li>B: Easy to overlook some phases of medication-use process</li> <li>E: Required element in the California (CA) Medication Error Reduction Plar (MERP)</li> </ul>
Avoid reliance on low-leverage strategies to prevent errors, and instead bundle these with mid- and high-leverage strategies	0	49	51	<ul> <li>B: Cost; technology limitations; high-leverage strategies not a leadership priority; overreliance on high-alert medication stickers</li> <li>E: None reported</li> </ul>
Limit the use of independent double checks to select high-alert medications with the greatest risk for error	3	31	66	B: Standardization within health systems; pediatric safety requirements E: Electronically controlling a few key independent double checks
Regularly assess for risk in safety systems and practices by using information from internal and external sources	0	31	69	<ul> <li>B: None reported</li> <li>E: Required element in the CA MERP; schedule time to review interna and external information and make the review a standing agenda item</li> </ul>
Establish outcome and process measures to monitor safety and routinely collect data to determine the effectiveness of strategies	6	53	41	B: Overreliance on voluntary reporting E: Required element in the CA MERP

\* For a full description and the exact wording of each Best Practice, please visit: www.ismp.org/node/160.